Overview

• In a recent Johns Hopkins study the multicancer early detection (MCED) lab test identified cancer-associated genetic material up to three years before clinical diagnosis.
• Researchers applied advanced genetic sequencing to 52 plasma samples originally collected for cardiovascular research and correctly flagged eight participants showing early tumor DNA.
• Early detection at this interval could enable intervention when tumors are less advanced and more likely to be curable, researchers say.
• Investigators emphasize the need for larger trials to confirm accuracy, establish clinical follow-up protocols and measure impact on cancer mortality.
• Results pave the way for potential annual or biennial blood screening programs across multiple cancer types pending further validation.